IBS is a common chronic condition that causes inflammation of the lining of the blood vessels in the body, usually through the development of red blood cells (RBCs) and platelets.
While the most common cause of this condition is Helicobacter pylori infection, the condition also causes many other common illnesses.
The Joint Committee on Non-Hodgkin Lymphoma, a group of scientists and physicians who work in the field of IBS treatment, recently presented its report on how IBS medications can prevent the development and progression of this debilitating condition.
The report says that by 2020, more than 100 million Israelis will suffer from this disease, which has an average life expectancy of only seven to 10 years.
“The IBS drugs may be effective in preventing the development or progression of IBD,” the committee said.
The JCPO’s report found that the development, or progression, of IB has been slowed down by IBS medication and by the prevention of platelets from being made.
“In fact, the use of these drugs in conjunction with chemotherapy in patients with non-HODGIN lymphoma may be able to reverse the development phase of the disease, and prevent further progression,” the report says.
However, some of the drugs in the JCPP report do not work in patients who have been diagnosed with non/Hodgin-positive HLA-B9 and/or non-HDL-B6, and may not be effective for treating HLA positive patients.
“These drugs do not improve the outcome of patients with HLA negative HLA,” the JEPP report said.
“The efficacy of these patients is not proven and is only suggested for the time being.”
The JEP report said that the JCEP should consider the possibility of combining a combination of drugs and/atypical agents to reduce the development time of the condition, and that the drug-related side effects of the combination should be considered.
However the report also said that if there is no treatment, it is recommended that the patients take a long course of anti-coagulant drugs to prevent clotting of blood vessels and reduce the amount of bleeding.
“In the absence of an effective treatment, the patients are urged to undergo a series of atypical therapies,” the study said.
According to the JCO, there are two main approaches to IBS: the standard treatment, and a novel, more complicated approach that uses different therapies to treat the condition.
For the standard IBS therapy, the JCAP said that in order to treat a person, he or she must have symptoms of Crohn’s disease or ulcerative colitis, as well as at least one of the following: fatigue, a weak immune system, nausea, diarrhea, joint pain, fever, dizziness, headache, or a rash.
For this treatment, patients must also be accompanied by a gastroenterologist, an allergist, an immunologist, a gastroentomologist, and an oncologist.
For a novel IBS, the committee recommended that patients must not have an autoimmune disease, or have been prescribed a non-drug therapy, such as steroids, anti-inflammatories, or corticosteroids.
“It is necessary to evaluate all the possible combinations of the two, but also to understand the side effects, and to evaluate the long-term effects,” the review concluded.